Zhimeng Biopharma Receives NMPA Approval to Begin Phase 2 Trial of Novel Potassium Channel Opener CB03-154 for Refractory Epilepsy

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154...

September 12, 2025 | Friday | News
QIAGEN Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Expands Syndromic Testing Panels

Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnosti...

September 11, 2025 | Thursday | News
InnoCare Pharma Wins Singapore HSA Approval for HIBRUKA Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA ...

September 09, 2025 | Tuesday | News
NurExone Biologic Secures US Patent Allowance for Proprietary Exosome Production Process Strengthening Global Market Position

NurExone Biologic Inc. , a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the United S...

September 09, 2025 | Tuesday | News
Certara Launches Pinnacle 21 Enterprise Plus to Streamline Clinical Data Specifications and Accelerate Regulatory Submissions

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, announced the availability of Pinnacle 21 Enterprise Plus. The solution enables clinical ...

September 05, 2025 | Friday | News
Boehringer Ingelheim’s HERNEXEOS® (zongertinib) Receives NMPA Approval for HER2-Mutant Advanced NSCLC in China

Boehringer Ingelheim  announced that China’s National Medical Products Administration (NMPA) has approved HERNEXEOS® (zongertinib tablets)...

September 02, 2025 | Tuesday | News
Roche and Alnylam Target Uncontrolled Hypertension with ZENITH Phase III Trial

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KA...

September 02, 2025 | Tuesday | News
Zai Lab Secures Hong Kong Approval for TIVDAK in Advanced Cervical Cancer

Zai Lab announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with r...

September 02, 2025 | Tuesday | News
Eisai Receives Orphan Drug Designation in Japan for Tazverik® in Rare Epithelioid Sarcoma

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received orphan drug designation for anticancer ...

September 01, 2025 | Monday | News
Sanofi’s Wayrilz Wins FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrate...

September 01, 2025 | Monday | News
Novotech and CTTQ Pharma Secure World’s First Approval of Anlotinib-Chemotherapy Combo for Advanced Soft Tissue Sarcoma

-Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Grou...

August 29, 2025 | Friday | News
United Therapeutics Exercises Option with MannKind to Develop Second Inhaled Therapy

MannKind Corporation announced that United Therapeutics Corporation  has exercised its option—granted under the companies’ 2018 lic...

August 28, 2025 | Thursday | News
Neopharma Technologies and Orient Gene Announce Global Partnership to Digitize Drug Testing with NEOVAULT® Integration

Neopharma Technologies Limited  announced a global software licensing and collaboration agreement with Zhejiang Orient Gene Biotech Co., Ltd. ("Orie...

August 26, 2025 | Tuesday | News
Valneva Faces US FDA Suspension of IXCHIQ® Vaccine Licence After New Safety Reports

  Valneva SE , a specialty vaccine company, announced that the United States Food and Drug Administration (FDA) has suspended the license for IX...

August 26, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close